BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 8112045)

  • 1. In vitro activity of three carbapenem antibiotics. Comparative studies with biapenem (L-627), imipenem, and meropenem against aerobic pathogens isolated worldwide.
    Hoban DJ; Jones RN; Yamane N; Frei R; Trilla A; Pignatari AC
    Diagn Microbiol Infect Dis; 1993; 17(4):299-305. PubMed ID: 8112045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antimicrobial activity of the new carbapenem biapenem compared to imipenem, meropenem and other broad-spectrum beta-lactam drugs.
    Sader HS; Jones RN
    Eur J Clin Microbiol Infect Dis; 1993 May; 12(5):384-91. PubMed ID: 8354307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In-vitro activity of biapenem, compared with imipenem and meropenem, against Pseudomonas aeruginosa strains and mutants with known resistance mechanisms.
    Chen HY; Livermore DM
    J Antimicrob Chemother; 1994 May; 33(5):949-58. PubMed ID: 8089068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of meropenem against imipenem-resistant bacteria and selection in vitro of carbapenem-resistant Enterobacteriaceae.
    Piddock LJ; Turner HL
    Eur J Clin Microbiol Infect Dis; 1992 Dec; 11(12):1186-91. PubMed ID: 1291320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative in vitro activity of biapenem, a new carbapenem antibiotic.
    Clarke AM; Zemcov SJ
    Eur J Clin Microbiol Infect Dis; 1993 May; 12(5):377-84. PubMed ID: 8354306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In-vitro activity of meropenem against clinical isolates obtained in Canada.
    Clarke AM; Zemcov SJ
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():47-55. PubMed ID: 2808216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative in-vitro activity of meropenem against clinical isolates including Enterobacteriaceae with expanded-spectrum beta-lactamases.
    Chanal C; Sirot D; Chanal M; Cluzel M; Sirot J; Cluzel R
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():133-41. PubMed ID: 2808205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative Activity of Carbapenem Testing (COMPACT) study in Germany.
    Valenza G; Seifert H; Decker-Burgard S; Laeuffer J; Morrissey I; Mutters R;
    Int J Antimicrob Agents; 2012 Mar; 39(3):255-8. PubMed ID: 22230334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In-vitro activity of meropenem against clinical isolates in a multicentre study in Italy.
    Schito GC; Sanna A; Chezzi C; Ravizzola G; Leone F; Molinari G; Menozzi MG; Pirali F
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():57-72. PubMed ID: 2681128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [in vitro activity of carbapenems against Enterobacteriaceae and Pseudomonas aeruginosa hyperproducers of group 1 chromosomal beta-lactamases].
    Martínez-Beltrán J; Calderón C; Sierra MP; Alvarez M; Cantón R
    Enferm Infecc Microbiol Clin; 1997 Sep; 15 Suppl 1():20-6. PubMed ID: 9410065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The comparative inhibitory and bactericidal activities of meropenem and imipenem against Acinetobacter spp. and Enterobacteriaceae resistant to second generation cephalosporins.
    MacGowan AP; Bowker KE; Bedford KA; Holt HA; Reeves DS; Hedges A
    J Antimicrob Chemother; 1995 Feb; 35(2):333-7. PubMed ID: 7759397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imipenem and meropenem activity against mecA-positive homogeneously and heterogeneously oxacillin-resistant and mecA-negative oxacillin-borderline-susceptible staphylococci.
    Knapp CC; Ludwig MD; Washington JA
    Diagn Microbiol Infect Dis; 1997 Jun; 28(2):81-6. PubMed ID: 9239499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [In vitro antibacterial activities of carbapenems against clinical isolates].
    Murase M
    Jpn J Antibiot; 1999 Nov; 52(11):667-79. PubMed ID: 10659443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activity of newer broad spectrum beta-lactam antibiotics against enterobacteriaceae and non-fermenters: a report from Austrian intensive care units. Austrian Carbapenem Susceptibility Surveillance Group.
    Krause R; Mittermayer H; Feierl G; Allerberger F; Wendelin I; Hirschl A; Reisinger EC
    Wien Klin Wochenschr; 1999 Jul; 111(14):549-54. PubMed ID: 10467641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro and in vivo evaluation of BO-2727 against imipenem- and/or meropenem-resistant Pseudomonas aeruginosa.
    Shibata K; Adachi Y; Kato E; Nagano R; Fuse A; Hashizume T; Ohtake N; Okamoto O; Nakagawa S
    J Antibiot (Tokyo); 1997 Feb; 50(2):135-8. PubMed ID: 9099222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multicenter in vitro evaluation of SM-7338, a new carbapenem.
    Jones RN; Aldridge KE; Allen SD; Barry AL; Fuchs PC; Gerlach EH; Pfaller MA
    Antimicrob Agents Chemother; 1989 Apr; 33(4):562-5. PubMed ID: 2658796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activity of biapenem against beta-lactamase producing Enterobacteriaceae.
    Alonso R; Fernández-Aranguiz A; Colom K; Morla A; Suinaga E; Umaran A; Cisterna R
    Eur J Clin Microbiol Infect Dis; 1994 Oct; 13(10):820-2. PubMed ID: 7889951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative in-vitro activity of meropenem against selected pathogens from hospitalized patients in The Netherlands. MASTIN Study Group.
    Endtz HP; van Dijk WC; Verbrugh HA
    J Antimicrob Chemother; 1997 Feb; 39(2):149-56. PubMed ID: 9069534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Comparative evaluation of in vitro activities of carbapenems against gram-negative pathogens: Turkish data of COMPACT study].
    Korten V; Söyletir G; Yalçın AN; Oğünç D; Dokuzoğuz B; Esener H; Ulusoy S; Tünger A; Aygen B; Sümerkan B; Arman D; Dizbay M; Akova M; Hasçelik G; Eraksoy H; Başaran S; Köksal I; Bayramoğlu G; Akalın H; Sınırtaş M
    Mikrobiyol Bul; 2011 Apr; 45(2):197-209. PubMed ID: 21644063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations.
    Jones RN; Huynh HK; Biedenbach DJ; Fritsche TR; Sader HS
    J Antimicrob Chemother; 2004 Jul; 54(1):144-54. PubMed ID: 15190031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.